SCHEMBL5400730

SCHEMBL5400730

COc1ccc(-c2cnc(N)nc2-c2c[nH]c(C(=O)N3CCCN(C)CC3)c2)cc1OC

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 2/20 0.49
HRH4 Q9H3N8 1/20 0.44
TLR9 Q9NR96 4/20 0.43
TLR8 Q9NR97 4/20 0.43
TLR7 Q9NYK1 4/20 0.43
PIK3CD O00329 1/20 0.42
PIK3CA P42336 1/20 0.42
PIK3CB P42338 1/20 0.42
PIK3CG P48736 1/20 0.42
KCNH2 Q12809 1/20 0.42
CCKAR P32238 1/20 0.42
CFTR P13569 1/20 0.42
KIT P10721 1/20 0.41
ADORA2A P29274 1/20 0.41
MAP4K1 Q92918 4/20 0.41
PRKCZ Q05513 1/20 0.40
IL2 P60568 2/20 0.40
KMT2A Q03164 1/20 0.40
MTOR P42345 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5405421 0.90 ADORA1 (0.53) ADORA1TLR8TLR7PIK3CDPIK3CA
SCHEMBL5405504 0.87 PRKCZ (0.55) ADORA1PIK3CACCKARKITADORA2A
SCHEMBL5404432 0.87 ADORA1 (0.52) ADORA1TLR9TLR8TLR7CCKAR
SCHEMBL5402140 0.86 HRH4 (0.46) ADORA1HRH4ADORA2AKMT2A
SCHEMBL27582134 0.86 ADORA1 (0.48) ADORA1TLR9TLR8TLR7PIK3CA
SCHEMBL5401735 0.85 ADORA1 (0.48) ADORA1PIK3CACCKARKITADORA2A
SCHEMBL5406975 0.85 ADORA1 (0.49) ADORA1HRH4PIK3CAADORA2AMTOR
SCHEMBL5407179 0.85 ADORA1 (0.47) ADORA1TLR9TLR8TLR7PIK3CA
SCHEMBL27582136 0.85 ADORA1 (0.47) ADORA1TLR9TLR8TLR7PIK3CA
SCHEMBL5403795 0.84 MAPK1 (0.55) ADORA1HRH4ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1363906-B1 HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF VERTEX PHARMA (US) 2015-07-15 EP claimed
US-6743791-B2 ANTICANCER AGENTS; ANTIINFLAMMATORY AGENTS VERTEX PHARMACEUTICALS INCORPORATED 2004-06-01 US claimed
US-20030092714-A1 Heterocyclic inhibitors of ERK2 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2003-05-15 US claimed
EP-1363906-B1 HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF VERTEX PHARMA (US) 2015-07-15 EP disclosed
US-20070265263-A1 Heterocyclic inhibitors of ERK2 and uses thereof CAO JINGRONG 2007-11-15 US disclosed
US-7253187-B2 Heterocyclic inhibitors of ERK2 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-08-07 US disclosed
US-20040229875-A1 Heterocyclic inhibitors of ERK2 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2004-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265263-A1 Heterocyclic inhibitors of ERK2 and uses thereof MAPK1, MAPK3, MAPKAPK2 ADORA1 4421/4885HRH4 1382/4885TLR9 3874/4885
US-20040229875-A1 Heterocyclic inhibitors of ERK2 and uses thereof MAPK1, MAPK3, MAP2K2 ADORA1 4106/4885HRH4 1807/4885TLR9 3597/4885
US-20030092714-A1 Heterocyclic inhibitors of ERK2 and uses thereof MAPK1, MAPK3, MAP2K2 ADORA1 4106/4885HRH4 1807/4885TLR9 3597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.